Evidence map›Paper›PMID 40251414›Full record

ArticleDiscover oncology2025

ZNF280A promotes malignant melanoma development through regulating cell proliferation, apoptosis, and cell cycle.

Wenjun Zheng, Zhuren Ruan, Yuanyuan Chen, Xianghui Li, Zhijian Yao, Gao Wei

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenjun Zheng *Department of Dermatology and Venerology, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, China.
Zhuren Ruan *Department of Dermatology and Venerology, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, China.
Yuanyuan Chen *Department of Dermatology and Venerology, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, China.
Xianghui LiDepartment of Dermatology and Venerology, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, China. doctorlixianghui@smail.nju.edu.cn.
Zhijian YaoDepartment of Dermatology and Venerology, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, China. yaozhijiankings@163.com.
Gao WeiDepartment of Dermatology and Venerology, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, 530021, China. weigao126@126.com.

Funding

China Postdoctoral Science Foundation 2023MD744193
6 · The paper itself

Abstract

Malignant melanoma (MM) is the most lethal skin cancer globally, with a high incidence of over 300,000 per year. Though constant efforts have been made to elucidate the mechanisms of MM, we are still away from a complete understanding. Recently, the essential role of zinc finger proteins in tumor development was covered, but none of these roles were explored in MM. Herein, we first identified a zinc finger protein ZNF280A that serves as the risk factor in MM prognosis and acted as a driver of MM development in vitro and in vivo. The level of ZNF280A was significantly higher in the 130 MM tissues than in 18 para-carcinoma tissues. Knockdown of ZNF280A contributed to the inhibition of cell proliferation, migration, and invasion in MM. Furthermore, the mechanism of increased apoptosis and stagnant cell cycle may be associated with p53 expression regulated by ZNF280A. In conclusion, our study first displayed that ZNF280A may promote the development of MM by regulating cell proliferation, migration, invasion, cell cycle, and apoptosis.

Indexed as

ApoptosisCell cycleMalignant melanomaP53ZNF280A

Identifiers

PMID40251414
PMCPMC12008104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.